Development of a Fluorescent Quenching Based High Throughput Assay to Screen for Calcineurin Inhibitors

• Abhisek Mukherjee ,

  * E-mail: marcie@orig3n.com (MAG); Abhisek.Mukherjee@uth.tmc.edu (AM)

  Affiliation Dept of Neurology, University of Texas Health Science Center, Houston, Texas, United States of America

  ⨯
• Kathleen Syeb,

  Current address: Ra Pharmaceuticals, Cambridge, Massachusetts, United States of America

  Affiliation Laboratory for Drug Discovery in Neurodegeneration, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Cambridge, Massachusetts, United States of America

  ⨯
• John Concannon,

  Current address: Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America

  Affiliation Laboratory for Drug Discovery in Neurodegeneration, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Cambridge, Massachusetts, United States of America

  ⨯
• Keri Callegari,

  Affiliation Dept of Neurology, University of Texas Health Science Center, Houston, Texas, United States of America

  ⨯
• Claudio Soto,

  Affiliation Dept of Neurology, University of Texas Health Science Center, Houston, Texas, United States of America

  ⨯
• Marcie A. Glicksman

  * E-mail: marcie@orig3n.com (MAG); Abhisek.Mukherjee@uth.tmc.edu (AM)

  Current address: ORIG3N, INC, Boston, Massachusetts, United States of America

  Affiliation Laboratory for Drug Discovery in Neurodegeneration, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Cambridge, Massachusetts, United States of America

  ⨯